In the ROADMAP study, patients with a HeartMate II ™ LVAD had a functional improvement in quality of life compared to optimal medical management The ROADMAP study was a prospective, multi-center ...

Fourteen people have died and 273 have been injured as a result of biological material building up over time in the grafts connecting both HeartMate II and HeartMate 3 left ventricular assist device ...

PHILADELPHIA -- Meticulous positioning matters in reducing stroke risk after left ventricular assist device (LVAD) placement, according to a researcher here. Two parameters of multi-detector cardiac ...

PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — In the MOMENTUM 3 study, a new continuous-flow magnetically levitated pump designed to prevent ...

CLEVELAND, OH — Researchers are warning about "unexpectedly" and "abruptly" increased rates of thrombosis with the HeartMate II (Thoratec) left ventricular assist device (LVAD) occurring early after ...

Please provide your email address to receive an email when new articles are posted on . Patients who received a new-generation left ventricular assist device experienced fewer ...

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

Thoratec ($THOR) credited a U.S. and global sales surge of its HeartMate II pump as a key factor in boosting 2012 first-quarter revenue 27% versus a year earlier. As ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...

ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...